We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Cell Fitness Status Detected from Nasal Swab Test Could Accurately Predict Hospitalization or Death in COVID-19 Patients

By LabMedica International staff writers
Posted on 19 Oct 2021

In the future, billions of COVID-19 nasal swab tests could not only tell if you have contracted COVID-19, but maybe even foretell if you are in danger of a serious infection. More...

In a new study, researchers from University of Copenhagen (Copenhagen, Denmark) have shown that the phenomenon cell fitness could predict the host immune response to a COVID-19-infection. The study has shown that analysis of a particular protein on the cell surface is likely to predict who is in danger of a serious infection caused by the virus. The discovery could prove to be important for pandemic management.

“Cells have a so-called fitness status, and by analyzing it we could predict hospitalization or death in COVID-19 patients, potentially making such a biomarker an earlier prediction tool, especially because it can be detected from the common nasal swab COVID-19-tests,” said Rajan Gogna from the Won Group at the Biotech Research & Innovation Centre.

If the cell fitness status is poor, it indicates that the cell does not develop well, either because the cell is aged, lacks reliability, has an ill-functioning metabolism or is disease prone etc. Earlier in 2021, the research team discovered that fitness status is expressed in proteins called flower proteins. These flower proteins are on the surface of the cell, and they are expressed in two forms, explained Gogna. Especially helpful in cases of the early phase of COVID-19 illness, the flower protein expression could accurately predict hospitalization or death as well predict who would have a less serious infection.

Cell fitness is relative to many things in our bodies and does not necessarily alter with age. Age has an impact, but the researchers have seen many cases from their database where people who are 80 years of age have a very good fitness profile of lungs, which is the main area where cell fitness is measured to predict COVID-19 infection outcome, explained Gogna. The researchers performed a post-mortem examination of the infected lung tissue in deceased COVID-19 patients to determine the flower proteins biological role in acute lung injury, which is the main cause of death from the disease. By using nasal swab samples, they also performed an observational study to evaluate whether the protein expression could accurately predict hospitalization or death.

“The method could predict who needed hospitalization with an accuracy of was 78.7%. With COVID-19 patients who would not have a serious infection, the prediction was accurate at 93.9%,” said Associate Professor and Group Leader Kyoung Jae Won, who analyzed the data using machine learning.

As parts of the Western world is slowly returning to normal, many countries in the low- and middle-income countries are still fighting and fearing new outbreaks of COVID-19. And for most it feels almost unbearable to endure another new wave of the virus, which could end in more deaths and long-term persistent symptoms from COVID-19 infection. The researchers hope their discovery is timely, because of the persistency of COVID-19 and rising cases and deaths in various nations outside the Western world despite vaccines.

“The cell fitness, expressed by the flower protein, could help explain why some people respond poorly to COVID-19 and provide opportunity for pre-identification of high-risk individuals. This discovery has the potential to help save their lives by severely alerting them to be extra protective of themselves, or until they are fortunate enough to get their hands on a vaccine. In some other nations, the population in general has great hesitancy against vaccination. But people are not hesitant about a test, and we hope this will improve outcomes,” added Gogna.

Related Links:
University of Copenhagen 


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.